55950 Investor Panel (1750 x 200 px) (9)

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event,
please get in touch at info@hansonwade.com

Cytokine-based therapies hold immense promise, but their development has been anything but simple. From early breakthroughs to unforeseen hurdles, the field has faced complex challenges in safety, efficacy, and clinical translation. Rather than seeing these obstacles as setbacks, the cytokine community came together to understand, refine, and innovate – turning challenges into opportunities together.

The 6th Cytokine-Based Drug Development Summit united the most influential leaders from Candel, Deka Biosciences, Regeneron, Sanofi, ModeX, OSE, and more to navigate the key translational and therapeutic index challenges —from overcoming systemic toxicities and improving specificity to engineering next-generation cytokine therapeutics with pro-drug, pulsed, targeted, and multi-specific immunomodulation strategies.

Participants engaged in intimate discussions and gained world-class insights through interactive workshops, roundtable discussions, and presentations to address the complexities of cytokine therapies and influence the future of immunotherapy.

At this pivotal time for cytokine drug developers, the summit drove innovation and helped break down barriers associated with systemic toxicity by improving the specificity and delivery of cytokine-based drugs.

Screenshot 2025-02-18 092721
Testimonial Banner

2025 Cytokine Trailblazers Include:

oncosec_medical_inc_logo

“After decades of research into the potential of cytokines to elicit antitumor immune responses, checkpoint inhibition appears to have made room for a new coming of age for cytokine therapy. It’s exciting to see the development of new technologies that can more precisely leverage the power and beauty of cytokine biology in this new era of cancer immunotherapy.” 

Bridget O’Keeffe
Vice President Clinical Development

This meeting brings together leaders in cytokine biology, therapeutic design, and immune oncology to collectively advance the development of targeted and effective cancer drugs. 

Jamie Spangler
Assistant Professor

Johns Hopkins University 

John Hopkins Ini